Close Menu


At a meeting hosted by the Partners HealthCare Center for Personalized Genetic Medicine last month, the events leading up to the re-labeling for colorectal cancer drugs Vectibix and Erbitux sparked discussion among participants about what Amgen and Bristol-Myers Squibb/ImClone knew about the drugs and when.

Nasdaq informed DeCode that it will suspend trading in the company’s common stock as of November 30, 2009.

The court approved Decode to continue operations under Chapter 11 bankruptcy protection, as well as its debtor-in-possession financing agreement with Saga.

Under the partnership, OptumHealth Allies' 15 million members will now have access to Pathway Genomics' health and ancestry gene scans at a 20 percent discount, which brings Pathway's $348 full health and ancestry gene scan package down to $278. Meanwhile, 23andMe's is raising the price of its health and ancestry gene scan package by an additional $100, to $499.

In addition to the filing for bankruptcy protection, Decode also has entered into an agreement to sell certain assets to Saga Investments.

The Mountain View, Calif.-based direct-to-consumer genomics firm has had a round of layoffs that it said were necessary to remain in business in a difficult economic climate. Competing DTC genomics firms have had cutbacks or are proceeding cautiously.

Decode has 30 days to make the interest payment or it will be in default.

Decode increased the principal amount of the promissory note to $2.9 million.

Decode expects that the closure and layoffs will cost it around $1.5 million in cash expenditures. It did not say how much it expects to save from the moves.

Steven Casper, director of the master of bioscience degree program at the Keck Graduate Institute of Applied Life Sciences, discusses a recent report assessing the Los Angeles region's life sciences strengths and shortcomings.


The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.